Mesa Laboratories (MLAB) EBITDA (2010 - 2026)

Mesa Laboratories has disclosed EBITDA across 17 years of filings, most recently posting $7.0 million for Q2 2026.

• In Q2 2026, EBITDA rose 129.47% year-over-year to $7.0 million; the TTM figure through Jun 2026 stood at $22.5 million (up 62.65% YoY), while the FY2026 annual figure was $18.5 million, up 13.31% from the prior year.
• EBITDA came in at $7.0 million for Q2 2026 at Mesa Laboratories, up from $2.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $8.0 million in Q4 2025 to a low of -$271.3 million in Q1 2024.
• Average EBITDA over 5 years is -$12.6 million, with a median of $2.9 million recorded in 2025.
• The largest YoY upside for EBITDA was 8725.37% in 2024 against a maximum downside of 52572.73% in 2024.
• Over 5 years, EBITDA stood at $3.4 million in 2022, then slumped by 101.97% to -$67000.0 in 2023, then soared by 8725.37% to $5.8 million in 2024, then surged by 38.0% to $8.0 million in 2025, then decreased by 11.84% to $7.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $7.0 million in Q2 2026, $2.7 million in Q1 2026, and $8.0 million in Q4 2025.